vs
Claritev Corp（CTEV）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Claritev Corp的季度营收约是Orthofix Medical Inc.的1.1倍（$246.6M vs $219.9M），Orthofix Medical Inc.净利率更高（-1.0% vs -32.7%，领先31.7%），Claritev Corp同比增速更快（6.2% vs 2.0%），Claritev Corp自由现金流更多（$36.4M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 2.5%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
CTEV vs OFIX — 直观对比
营收规模更大
CTEV
是对方的1.1倍
$219.9M
营收增速更快
CTEV
高出4.2%
2.0%
净利率更高
OFIX
高出31.7%
-32.7%
自由现金流更多
CTEV
多$19.6M
$16.8M
两年增速更快
OFIX
近两年复合增速
2.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $246.6M | $219.9M |
| 净利润 | $-80.6M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | -3.1% | 0.2% |
| 净利率 | -32.7% | -1.0% |
| 营收同比 | 6.2% | 2.0% |
| 净利润同比 | 41.6% | 92.4% |
| 每股收益（稀释后） | $-4.88 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTEVOFIX
| Q4 25 | $246.6M | $219.9M | ||
| Q3 25 | $246.0M | $205.6M | ||
| Q2 25 | $241.6M | $203.1M | ||
| Q1 25 | $231.3M | $193.6M | ||
| Q4 24 | $232.1M | $215.7M | ||
| Q3 24 | $230.5M | $196.6M | ||
| Q2 24 | $233.5M | $198.6M | ||
| Q1 24 | $234.5M | $188.6M |
净利润CTEVOFIX
| Q4 25 | $-80.6M | $-2.2M | ||
| Q3 25 | $-69.8M | $-22.8M | ||
| Q2 25 | $-62.6M | $-14.1M | ||
| Q1 25 | $-71.3M | $-53.1M | ||
| Q4 24 | $-138.0M | $-29.1M | ||
| Q3 24 | $-391.4M | $-27.4M | ||
| Q2 24 | $-576.7M | $-33.4M | ||
| Q1 24 | $-539.7M | $-36.0M |
毛利率CTEVOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率CTEVOFIX
| Q4 25 | -3.1% | 0.2% | ||
| Q3 25 | 4.1% | -8.3% | ||
| Q2 25 | 6.9% | -7.9% | ||
| Q1 25 | 4.2% | -25.2% | ||
| Q4 24 | -17.8% | -5.3% | ||
| Q3 24 | -146.7% | -9.6% | ||
| Q2 24 | -224.4% | -12.5% | ||
| Q1 24 | -207.4% | -15.6% |
净利率CTEVOFIX
| Q4 25 | -32.7% | -1.0% | ||
| Q3 25 | -28.4% | -11.1% | ||
| Q2 25 | -25.9% | -6.9% | ||
| Q1 25 | -30.8% | -27.4% | ||
| Q4 24 | -59.4% | -13.5% | ||
| Q3 24 | -169.8% | -13.9% | ||
| Q2 24 | -247.0% | -16.8% | ||
| Q1 24 | -230.1% | -19.1% |
每股收益（稀释后）CTEVOFIX
| Q4 25 | $-4.88 | $-0.05 | ||
| Q3 25 | $-4.23 | $-0.57 | ||
| Q2 25 | $-3.81 | $-0.36 | ||
| Q1 25 | $-4.38 | $-1.35 | ||
| Q4 24 | $-8.49 | $-0.76 | ||
| Q3 24 | $-24.25 | $-0.71 | ||
| Q2 24 | $-35.78 | $-0.88 | ||
| Q1 24 | $-33.40 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $16.8M | $82.0M |
| 总债务越低越好 | $4.6B | — |
| 股东权益账面价值 | $-173.9M | $450.0M |
| 总资产 | $4.9B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTEVOFIX
| Q4 25 | $16.8M | $82.0M | ||
| Q3 25 | $39.2M | $62.9M | ||
| Q2 25 | $56.4M | $65.6M | ||
| Q1 25 | $23.1M | $58.0M | ||
| Q4 24 | $16.8M | $83.2M | ||
| Q3 24 | $86.6M | $30.1M | ||
| Q2 24 | $48.8M | $26.4M | ||
| Q1 24 | $58.7M | $27.0M |
总债务CTEVOFIX
| Q4 25 | $4.6B | — | ||
| Q3 25 | $4.5B | $157.2M | ||
| Q2 25 | $4.5B | $157.0M | ||
| Q1 25 | $4.5B | $156.9M | ||
| Q4 24 | $4.5B | $157.0M | ||
| Q3 24 | $4.5B | $118.5M | ||
| Q2 24 | $4.5B | $118.0M | ||
| Q1 24 | $4.5B | $118.2M |
股东权益CTEVOFIX
| Q4 25 | $-173.9M | $450.0M | ||
| Q3 25 | $-101.8M | $442.5M | ||
| Q2 25 | $-39.9M | $458.3M | ||
| Q1 25 | $14.8M | $458.3M | ||
| Q4 24 | $84.0M | $503.1M | ||
| Q3 24 | $207.6M | $525.9M | ||
| Q2 24 | $603.4M | $546.0M | ||
| Q1 24 | $1.2B | $570.3M |
总资产CTEVOFIX
| Q4 25 | $4.9B | $850.6M | ||
| Q3 25 | $5.0B | $832.6M | ||
| Q2 25 | $5.1B | $837.2M | ||
| Q1 25 | $5.1B | $823.1M | ||
| Q4 24 | $5.2B | $893.3M | ||
| Q3 24 | $5.3B | $867.9M | ||
| Q2 24 | $5.7B | $882.0M | ||
| Q1 24 | $6.4B | $906.0M |
负债/权益比CTEVOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | 304.87× | 0.34× | ||
| Q4 24 | 53.67× | 0.31× | ||
| Q3 24 | 21.73× | 0.23× | ||
| Q2 24 | 7.48× | 0.22× | ||
| Q1 24 | 3.85× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $66.3M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $36.4M | $16.8M |
| 自由现金流率自由现金流/营收 | 14.8% | 7.6% |
| 资本支出强度资本支出/营收 | 12.1% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-12.3M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流CTEVOFIX
| Q4 25 | $66.3M | $27.7M | ||
| Q3 25 | $19.9M | $12.4M | ||
| Q2 25 | $61.2M | $11.6M | ||
| Q1 25 | $-30.1M | $-18.4M | ||
| Q4 24 | $-33.4M | $23.7M | ||
| Q3 24 | $72.8M | $11.7M | ||
| Q2 24 | $18.5M | $9.0M | ||
| Q1 24 | $49.7M | $-18.6M |
自由现金流CTEVOFIX
| Q4 25 | $36.4M | $16.8M | ||
| Q3 25 | $-16.3M | $2.5M | ||
| Q2 25 | $36.6M | $4.5M | ||
| Q1 25 | $-68.9M | $-25.1M | ||
| Q4 24 | $-63.8M | $15.2M | ||
| Q3 24 | $41.1M | $6.3M | ||
| Q2 24 | $-7.0M | $-360.0K | ||
| Q1 24 | $19.2M | $-29.1M |
自由现金流率CTEVOFIX
| Q4 25 | 14.8% | 7.6% | ||
| Q3 25 | -6.6% | 1.2% | ||
| Q2 25 | 15.2% | 2.2% | ||
| Q1 25 | -29.8% | -13.0% | ||
| Q4 24 | -27.5% | 7.0% | ||
| Q3 24 | 17.8% | 3.2% | ||
| Q2 24 | -3.0% | -0.2% | ||
| Q1 24 | 8.2% | -15.4% |
资本支出强度CTEVOFIX
| Q4 25 | 12.1% | 4.9% | ||
| Q3 25 | 14.7% | 4.8% | ||
| Q2 25 | 10.2% | 3.5% | ||
| Q1 25 | 16.8% | 3.5% | ||
| Q4 24 | 13.1% | 4.0% | ||
| Q3 24 | 13.8% | 2.7% | ||
| Q2 24 | 10.9% | 4.7% | ||
| Q1 24 | 13.0% | 5.6% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTEV
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
